Philip Nickson
Algemeen Adviseur bij MONTE ROSA THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
Philip Nickson is currently the Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. He previously worked as the Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Dr. Nickson holds a doctorate degree from The University of Manchester and a graduate degree from Suffolk University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-01-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Philip Nickson
| Bedrijven | Functie | Begin |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Algemeen Adviseur | 01-03-2021 |
Eerdere bekende functies van Philip Nickson
| Bedrijven | Functie | Einde |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2021 |
Opleiding van Philip Nickson
| Suffolk University | Graduate Degree |
| The University of Manchester | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
